{
    "clinical_study": {
        "@rank": "8064", 
        "arm_group": {
            "arm_group_label": "Treatment (monoclonal antibody, antiangiogenesis)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This pilot phase II trial studies how well giving bevacizumab works in treating patients\n      with relapsed prostate cancer that did not respond to hormone therapy. Monoclonal\n      antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the\n      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or\n      tumor-killing substances to them. Bevacizumab may also stop the growth of prostate cancer by\n      blocking blood flow to the tumor"
        }, 
        "brief_title": "Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Adenocarcinoma of the Prostate", 
            "Recurrent Prostate Cancer", 
            "Stage I Prostate Cancer", 
            "Stage IIA Prostate Cancer", 
            "Stage IIB Prostate Cancer", 
            "Stage III Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. The rate of prostate-specific antigen (PSA) response with avastin (bevacizumab) therapy\n      in androgen independent non-metastatic prostate cancer.\n\n      II. Toxicities associated with avastin therapy. III. Time to PSA progression.\n\n      SECONDARY OBJECTIVES:\n\n      I. Overall survival of androgen independent non-metastatic prostate cancer patients treated\n      with avastin.\n\n      II. The change in PSA velocity with avastin therapy in androgen-independent non-metastatic\n      prostate cancer.\n\n      III. Time to distant metastatic disease. IV. Circulating tumor cell count. V. Changes in\n      levels of N terminal collagen peptide and bone-specific alkaline phosphatase with avastin\n      therapy.\n\n      VI. Correlation of crosslinked N-telopeptide of type I collagen (NTX) and serum\n      B-Cell-Specific Activator Protein (BSAP) levels with time to PSA progression.\n\n      OUTLINE:\n\n      Patients receive bevacizumab intravenously (IV) over 30-90 minutes once every 14 days.\n      Courses repeat every 14 days in the absence of disease progression and unacceptable\n      toxicity.\n\n      After completion of study treatment, patients are followed up every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A histologic diagnosis of prostate adenocarcinoma.\n\n          -  No evidence of bone/visceral metastases as visualized on standard imaging such as\n             bone scan, chest X-ray, CT scan or MRI of abdomen and pelvis.\n\n          -  PSA-only progression despite androgen deprivation therapy. PSA progression is defined\n             as 3 rising levels, with a minimum interval of 2 weeks between each determination.\n             The last determination must have a minimum value of\n\n             1ng/ml and be determined within two weeks prior to registration. If the second or\n             third confirmatory value is less than the previous value, the patient will still be\n             eligible if a repeat value (No. 4) is found to be greater than all the prior values.\n\n          -  If patient has been on antiandrogen in the past 28 days, then PSA progression after\n             withdrawal period (28 days for flutamide and 42 days for bicalutamide or nilutamide)\n             is required.\n\n          -  ECOG performance status of 0-1.\n\n          -  No prior avastin therapy.\n\n          -  No investigational or commercial agents or therapies (except LHRH agonists) may be\n             administered concurrently with the intent to treat the patient's malignancy. Patients\n             on LHRH agonists must continue the use of LHRH agonist therapy. Bisphosphonates can\n             be administered per treating physician discretion.\n\n          -  At least 4 weeks must have elapsed since prior systemic therapy, except for LHRH\n             analogue therapy and steroids. If steroids are being used for therapy of prostate\n             cancer, these should be discontinued prior to starting avastin therapy.\n\n          -  Age \u2265 18 years.\n\n          -  Life expectancy of at least 6 months.\n\n          -  Ability to understand and the willingness to sign a written informed consent that is\n             approved by the Institutional Human Investigation Committee.\n\n          -  Use of effective means of contraception in subjects.\n\n        Exclusion Criteria:\n\n        Inability to comply with study and/or follow-up procedures.\n\n          -  Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or\n             diastolic blood pressure > 100 mmHg on antihypertensive medications).\n\n          -  Any prior history of hypertensive crisis or hypertensive encephalopathy.\n\n          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see\n             Appendix E).\n\n          -  History of myocardial infarction or unstable angina within last 12 months prior to\n             study enrollment.\n\n          -  History of stroke or transient ischemic attack within 6 months prior to study\n             enrollment.\n\n          -  Known CNS disease.\n\n          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection).\n\n          -  Symptomatic peripheral vascular disease.\n\n          -  Evidence of bleeding diathesis or coagulopathy.\n\n          -  Patients on anticoagulants are allowed if patient has been on therapy for at least 4\n             weeks and patient has no acute thromboembolic activity.\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within. 28\n             days prior to study enrollment or anticipation of need for major surgical procedure\n             during the course of the study.\n\n          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular\n             access device, within 7 days prior to study enrollment.\n\n          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess within 6 months prior to study enrollment.\n\n          -  Serious, non-healing wound, ulcer, or bone fracture.\n\n          -  Proteinuria at screening as demonstrated by:\n\n             1. Urine protein:creatinine (UPC) ratio \u2265 1.0 at screening\n\n          -  Known hypersensitivity to any component of avastin.\n\n          -  Refusal to use effective means of contraception.\n\n          -  Patients with known brain metastases should be excluded from this clinical trial\n             because of their poor prognosis and because they often develop progressive neurologic\n             dysfunction that would confound the evaluation of neurologic and other adverse\n             events.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to avastin.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Patients with immune deficiency such as HIV-positive patients or those receiving\n             combination anti-retroviral therapy are excluded from the study because of lack of\n             safety data for avastin in these patients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00478413", 
            "nct_id": "NCT01656304", 
            "org_study_id": "2006-064", 
            "secondary_id": "NCI-2011-00661"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (monoclonal antibody, antiangiogenesis)", 
                "description": "Given IV", 
                "intervention_name": "bevacizumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-VEGF humanized monoclonal antibody", 
                    "anti-VEGF monoclonal antibody", 
                    "Avastin", 
                    "rhuMAb VEGF"
                ]
            }, 
            {
                "arm_group_label": "Treatment (monoclonal antibody, antiangiogenesis)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Barbara Ann Karmanos Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Bevacizumab in PSA Relapse Androgen Independent Prostate Cancer (AVF3952sn)", 
        "overall_official": {
            "affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "last_name": "Ulka Vaishampayan", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Response rates will be summarized by point estimates and Wilson type 80% confidence intervals.", 
                "measure": "PSA response rate with bevacizumab therapy in androgen independent non-metastatic prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "An average every 6 weeks for up to 3 months"
            }, 
            {
                "description": "Toxicity rates will be summarized by point estimates and Wilson type 80% confidence intervals. Toxicities will be graded per the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), and PSA response will be determined as per PSA Working Group response criteria. Censored time to PSA progression will be estimated with standard Kaplan-Meier methodology.", 
                "measure": "Toxicities associated with bevacizumab therapy", 
                "safety_issue": "Yes", 
                "time_frame": "An average of every 2 weeks while on therapy"
            }, 
            {
                "description": "TTPP will be measured from protocol registration to appearance of PSA progression as defined by the criteria of the PSA Working Group response criteria. The end point for progression will be calculated at the time a 25% increase in PSA has been achieved. PSA velocity will also be calculated as change in PSA doubling time pre and post therapy and the rate of PSA rise pre- and post-therapy.", 
                "measure": "Time to PSA progression (TTPP)", 
                "safety_issue": "No", 
                "time_frame": "An average every 6 weeks for up to 3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656304"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival of androgen independent non-metastatic prostate cancer patients treated with bevacizumab", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months"
            }, 
            {
                "measure": "The change in PSA velocity with bevacizumab therapy in androgen independent non-metastatic prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "Baseline, every 6 weeks while on therapy, and then every 3 months thereafter"
            }, 
            {
                "measure": "Time to distant metastatic disease", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months"
            }, 
            {
                "measure": "Circulating tumor cell count", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 12"
            }, 
            {
                "measure": "Changes in levels of N terminal collagen peptide and bone-specific alkaline phosphatase with bevacizumab therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 7 or 12, and post-therapy"
            }, 
            {
                "measure": "Correlation of urine NTX and serum BSAP levels with time to PSA progression", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 7 or 12 and post-therapy"
            }
        ], 
        "source": "Barbara Ann Karmanos Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Barbara Ann Karmanos Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2007", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}